Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Summar Elmorshidy

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

S.M. Elmorshidy1, O.N. Abd Elffatah2, H.H. Essa2, A.K. Ibrahim3, D. Sayed4, S. Shehata2

Author affiliations

  • 1 Clinical Oncology, Assiut University Hospitals, 71516 - Assiut/EG
  • 2 Clinical Oncology, Assiut University Hospitals, Assiut/EG
  • 3 Community Medicine Department, Assiut University Hospital, Faculty of Medicine, Assiut University, Egypt, 002 - Assiut/EG
  • 4 Clinical Pathology, South Egypt Cancer Institute, Assiut/EG
More

Resources

Abstract 738

Background

Still, there is no clinically reliable marker to detect micro-metastasis or breast cancer relapse. This study aimed to evaluate the role of circulating tumor cells (CTCs) as a biomarker in non-metastatic breast cancer patients.

Methods

CTCs quantification was carried out using flow cytometry for 50 breast cancer patients post-operatively on three intervals; before starting, after three cycles and at the end of adjuvant chemotherapy. The relationship between CTCs and other tumor characteristics and outcomes were studied.

Results

The median follow-up duration was 35 months. Before starting adjuvant chemotherapy, CTCs were positive (cut off point ≥5) in 36% of the patients and dropped to 20% after finishing chemotherapy (P = 0.04). There was a strong negative correlation (r=-0.89) between change in the CTC levels from baseline till mid-treatment (3 cycles) and from this point to the end of treatment (6 cycles) (R2=79.2). CTCs were detected in 88.9% (n = 16 of 18) of node-positive patients and in 11.1% of node-negative patients (n = 2 of 18, p-value =0.04). No significant association was found with tumor size, grading, or hormone receptor status. Distant metastasis was detected in 20% (n = 10 of 50) of patients and was significantly associated with CTCs ≥ 5 in 80 % of them (n = 8 of 10) p-value =0.01. The presence of ≥ 5 CTCs at baseline was associated with reduction in both the disease-free survival and overall survival (p-value <0.001 and =0.003, respectively) . Baseline CTCs ≥5 were confirmed as an independent prognostic factor in multivariate cox hazard regression analysis for DFS (HR = 3.71; 95% CI = 1.62-8.48; p-value=0.002 and OS (HR = 3.14; 95% CI = 1.34-7.37;p-value= 0.009).

Conclusions

The findings of the current work suggested that the presence of ≥ 5 CTCs at baseline would predict early disease recurrence and reduce the overall survival in primary, non-metastatic breast cancer patients receiving adjuvant chemotherapy. Thereby, peripherally detected CTCs could be used as a new prognostic marker for identification of early relapse and survival reduction.

Clinical trial identification

Legal entity responsible for the study

Assiut University, Egypt.

Funding

Assiut University Hospitals, Egypt.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings